Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-025-07455-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of metastasis-free survival in patients with localized prostate adenocarcinoma using primary tumor and lymph node radiomics from pre-treatment PSMA-PET/CT scans.
Radiother Oncol
September 2025
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Purpose: To predict metastasis-free survival (MFS) for patients with prostate adenocarcinoma (PCa) treated with androgen deprivation therapy (ADT) and external radiotherapy using clinical factors and radiomics extracted from primary tumor and node volumes in pre-treatment PSMA PET/CT scans.
Materials/methods: Our cohort includes 134 PCa patients (nodal involvement in 28 patients). Gross tumor volumes of primary tumor (GTVp) and nodes (GTVn) on CT and PET scans were segmented.
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.
Front Oncol
August 2025
Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, United States.
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [Lu]Lu-PSMA-617 and guide therapy decision-making.
View Article and Find Full Text PDFAI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis.
EJNMMI Res
August 2025
Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Background: Body composition (BC) analysis is performed to quantify the relative amounts of different body tissues as a measure of physical fitness and tumor cachexia. We hypothesized that relative changes in body composition (BC) parameters, assessed by an artificial intelligence-based, PACS-integrated software, between baseline imaging before the start of radioligand therapy (RLT) and interim staging after two RLT cycles could predict overall survival (OS) in patients with metastatic castration-resistant prostate cancer.
Methods: We conducted a single-center, retrospective analysis of 92 patients with mCRPC undergoing [Lu]Lu-PSMA RLT between September 2015 and December 2023.
Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.
Int J Mol Sci
August 2025
Department of Radiation Oncology, GenesisCare Spain, Hospital Universitario Vithas La Milagrosa, 28003 Madrid, Spain.
Prostate-specific antigen (PSA) has been the primary biomarker used for the detection and monitoring of prostate cancer for decades. However, its limited specificity and prognostic accuracy have led to the development of novel molecular and imaging biomarkers aimed at improving the clinical characterization of localized disease. This review critically examines recent advances in urinary biomarkers (e.
View Article and Find Full Text PDFRadioligand treatment with [Lu]Lu-PSMA I&T in elderly Patients - Safety, efficacy, and prognostic factors for survival.
Eur J Nucl Med Mol Imaging
August 2025
Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.
Purpose: We aimed to evaluate the safety and efficacy to explore predictors of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC) patients aged ≥ 75 and explored baseline predictors of overall survival (OS).
Materials And Methods: 56 men (median age 78, range 75-95) were treated with RLT. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.